GlassScriptPhysician profile
Michele Hernandez
NPI 1982954541
$8,528.59
in general payments reported to CMS, 2019-2025
33 companies · $1,441 in 2025
The $1,441 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,458 · 2022: $1,514 · 2023: $1,828 · 2024: $1,289 · 2025: $1,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,492 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,492.25 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,437.01 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $1,415.45 | 2021 | |
| Abbvie INC. | $1,144.74 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,083.87 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $436.44 | 2021-2025 | |
| Lilly USA, LLC | $432.61 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $361.20 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $280.00 | 2023-2025 | Repatha, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $256.87 | 2021-2025 | Xifaxan |
| Gilead Sciences, INC. | $165.43 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.01 | 2021-2024 | Jardiance |
| Inspire Medical Systems, INC. | $143.08 | 2024-2025 | Inspire |
| Amarin Pharma, INC. | $139.58 | 2021-2023 | |
| Abbott Laboratories | $131.37 | 2023-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $123.78 | 2025 | Voquezna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $123.00 | 2025 | |
| Astellas Pharma US INC | $115.69 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.65 | 2021-2022 | |
| Neos Therapeutics, LP | $71.63 | 2022-2023 | Adzenys Xr-Odt |
| Exact Sciences Corporation | $68.98 | 2025 | Cologuard Collection Kit |
| Corium, LLC | $61.78 | 2023 | Azstarys |
| Dexcom, INC. | $57.09 | 2022-2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $43.54 | 2021-2025 | Gardasil 9, Capvaxive |
| Ibsa Pharma INC. | $39.60 | 2025 | Tirosint, Licart, Flector |
| Boston Scientific Corporation | $35.42 | 2022 | |
| Intuity Medical INC | $21.65 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Sanofi Pasteur INC. | $19.58 | 2023 | |
| Dynavax Technologies Corporation | $19.03 | 2023 | Heplisav-B |
| Verity Pharmaceuticals INC. | $18.44 | 2025 | Tlando |
| Paratek Pharmaceuticals, INC. | $15.81 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.00 | 2022 | |
| Currax Pharmaceuticals LLC | $13.80 | 2025 | Contrave |
| Genentech USA, INC. | $2.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.